Visual contrast sensitivity in Alzheimer's disease, mild cognitive impairment, and older adults with cognitive complaints

dc.contributor.authorRisacher, Shannon L.
dc.contributor.authorWuDunn, Darrell
dc.contributor.authorPepin, Susan M.
dc.contributor.authorMaGee, Tamiko R.
dc.contributor.authorMcDonald, Brenna C.
dc.contributor.authorFlashman, Laura A.
dc.contributor.authorWishart, Heather A.
dc.contributor.authorPixley, Heather S.
dc.contributor.authorRabin, Laura A.
dc.contributor.authorParé, Nadia
dc.contributor.authorEnglert, Jessica J.
dc.contributor.authorSchwartz, Eben
dc.contributor.authorCurtain, Joshua R.
dc.contributor.authorWest, John D.
dc.contributor.authorO’Neill, Darren P.
dc.contributor.authorSantulli, Robert B.
dc.contributor.authorNewman, Richard W.
dc.contributor.authorSaykin, Andrew J.
dc.contributor.departmentRadiology and Imaging Sciences, School of Medicine
dc.date.accessioned2025-06-12T10:20:48Z
dc.date.available2025-06-12T10:20:48Z
dc.date.issued2013
dc.description.abstractDeficits in contrast sensitivity (CS) have been reported in Alzheimer's disease (AD). However, the extent of these deficits in prodromal AD stages, including mild cognitive impairment (MCI) or even earlier, has not been investigated. In this study, CS was assessed using frequency doubling technology in older adults with AD (n = 10), amnestic MCI (n = 28), cognitive complaints without performance deficits (CC; n = 20), and healthy controls (HC; n = 29). The association between CS and cognition was also evaluated. Finally, the accuracy of CS measures for classifying MCI versus HC was evaluated. CS deficits were found in AD and MCI, while CC showed intermediate performance between MCI and HC. Upper right visual field CS showed the most significant difference among groups. CS was also associated with cognitive performance. Finally, CS measures accurately classified MCI versus HC. The CS deficits in AD and MCI, and intermediate performance in CC, indicate that these measures are sensitive to early AD-associated changes. Therefore, frequency doubling technology-based measures of CS may have promise as a novel AD biomarker.
dc.eprint.versionAuthor's manuscript
dc.identifier.citationRisacher SL, Wudunn D, Pepin SM, et al. Visual contrast sensitivity in Alzheimer's disease, mild cognitive impairment, and older adults with cognitive complaints. Neurobiol Aging. 2013;34(4):1133-1144. doi:10.1016/j.neurobiolaging.2012.08.007
dc.identifier.urihttps://hdl.handle.net/1805/48636
dc.language.isoen_US
dc.publisherElsevier
dc.relation.isversionof10.1016/j.neurobiolaging.2012.08.007
dc.relation.journalNeurobiology of Aging
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectContrast sensitivity (CS)
dc.subjectFrequency doubling technology (FDT)
dc.subjectAlzheimer’s disease (AD)
dc.subjectMild cognitive impairment (MCI)
dc.subjectCognitive complaints
dc.subjectBiomarker
dc.subjectVision
dc.titleVisual contrast sensitivity in Alzheimer's disease, mild cognitive impairment, and older adults with cognitive complaints
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Risacher2013Visual-AAM.pdf
Size:
2.37 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: